Overview

Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate RLS103 for safety and suppression of the epileptic photoparoxysmal response compared to placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Receptor Life Sciences
Collaborator:
The Epilepsy Study Consortium